Navigation Links
ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits
Date:9/22/2009

SALEM, N.H., Sept. 22 /PRNewswire/ -- ALPCO is pleased to introduce a pair of ELISA kits for research use only for the easy and accurate measurement of both active (7-36) GLP-1 and combined (7-36 and 9-36) GLP-1 fragments.

GLP-1, an incretin hormone, has been a focus of the diabetes & obesity research community recently. The first incretin therapy was approved by the FDA in 2006, and early clinical data demonstrates that these therapies are delivering good results for some patients with Type II diabetes. As more incretin-based drugs are identified and proceed through the clinical development process, the area of research that focuses on elucidating the physiological impact of incretin hormones has taken on greater significance. Craig LaMarca, a scientist and technical sales advisor at ALPCO, points out: "Basic science researchers are establishing mechanisms and principles for why GLP-1 is an attractive therapeutic target. Along these same lines, but further down in the process are pharmaceutical companies who are trying to establish the functionality of potential drug candidates in their ability to increase circulating levels of GLP-1... Although most of the work currently is focusing on diabetes, recent research has implied utility of targeting GLP-1 in other therapeutic areas." For example, studies have shown that GLP-1 agonists and/or DPP-IV inhibitors offer Beta cell protection in rodents(1) - an indication that the same may be accomplished in humans, offering the hope of altering the progression of Type II diabetes. On the other hand, studies have also proposed that there is a cardioprotective and vasodilatory role for the 9-36 fragment, a peptide once thought to be relatively biologically inactive(2).

These efforts are currently hampered by a lack of good tools, as we are reminded by Mr. LaMarca: "With all of the drug development and basic research efforts ongoing, there is no accessible commercial method for quantification of circulating GLP-1, either in its active or total form. Researchers have been forced to use assays that have several systemic issues including: lack of reproducibility, inability to detect significant physiological shifts of GLP-1 resulting from meal tolerance or therapeutic intervention and lack of sensitivity. Since fasting levels are so low, researchers are often unable to establish a baseline."

Marking a turning point in GLP-1 ELISA technology, the ALPCO/Epitope ELISA answers the need for a reproducible, highly sensitive assay to measure Active (7-36) GLP-1. This offering is enhanced by a corresponding method for detecting combined (7-36 and 9-36) fragments. The Active (7-36) assay is sensitive to 0.2 pmol/l, allowing researchers to discern low baseline values. Additionally, both kits demonstrate a marked stimulation index for fed versus fasted samples, a capability that has been lacking for commercial kits previously available to researchers.

(1) Suarez-Pinon W, et al. 2008. Diabetes; 57 (12): 3281-3288.

(2) Ban K, et al. 2008. Circulation; 117: 2340-2350

Media contact: Kate Kaplan, 1-800-592-5726 x220


'/>"/>
SOURCE ALPCO
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Us TOO Launches National SEA Blue Campaign for Prostate Cancer Awareness Month
2. UPMC Health Plan Launches New Personal Health Record
3. HealthInsuranceFinders.com Launches Video Contest for Young Directors
4. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
5. Keeping Kids Healthy and Fit: The New York Kids Club Launches a Revolutionary New Fitness Program
6. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
7. Mannatech Launches Phase One of New Sales and Training Tools
8. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
9. Actavis Launches Carvedilol Tablets in the U.S.
10. MedQuist Re-launches New, Improved Web Site
11. Elsevier launches new journal: Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2017)... (PRWEB) , ... September 24, 2017 , ... The Tuscany ... on TripAdvisor and one of Provo's premier boutique resorts, is planning on re-opening the ... the resort after devastating Hurricanes Irma and more recently Hurricane Maria, and the staff ...
(Date:9/24/2017)... ... September 24, 2017 , ... “The Messiah 8 with the ... texts to firsthand experiences. “The Messiah 8 with the 3rd Anti Christ” is the ... I’ve tried to look at all the angles of life,” Velazquez states, “I always ...
(Date:9/24/2017)... ... September 24, 2017 , ... “Star of Bethlehem Study”: is ... Study” is the creation of published author, Duane Engdahl, an investigator who had has ... Faith Publishing, Duane Engdahl’s new book is a thought-provoking essay an event so significant ...
(Date:9/23/2017)... ... September 23, 2017 , ... A September 5 ... Robert Kushner, director of Chicago’s Center for Lifestyle Medicine at Northwestern Medicine. While ... article notes that the center routinely recommends weight loss surgeries for patients who ...
(Date:9/23/2017)... ... ... Can't Win Them All”: the story of an entrepreneur and a family man whose ... lives of young athletes. “You Can't Win Them All” is the creation of ... small town in Northern Ontario, Canada. He is an entrepreneur who manages to ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a leader ... will host an educational session focused on the role ... (CLABSI) prevention at the 2017 Annual Scientific Meeting of ... take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s Prevantics® ...
(Date:9/5/2017)... Sept. 5, 2017  Getinge, a leading global ... vibrant charitable donation program -- "Color for the ... heart defect research by The Children,s Heart Foundation. ... general public are encouraged to download a coloring ... completed artwork to the gallery on the website. ...
(Date:9/1/2017)... WHIPPANY, N.J. , Sept. 1, 2017  Bayer will ... at the European Society for Medical Oncology (ESMO) 2017 Congress, ... studies presented will include new preclinical and clinical data on ... from two earlier pipeline projects. ... of the best minds in cancer research at ESMO," said ...
Breaking Medicine Technology: